pancreatic cancer
Conditions
Interventions
Duodenal fluid is collected using a catheter during ERCP.
Sponsors
Kyushu university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: [Cases of pancreatic ductal carcinoma or suspected pancreatic ductal carcinoma] 1: The age at the time of consent is 18 years or older. 2: Patients with pancreatic ductal carcinoma or suspected pancreatic ductal carcinoma who are expected to undergo surgery and are scheduled to undergo ERCP for preoperative testing (excluding obvious stage IV pancreatic cancer). 3: The patient is given an explanation using an explanatory document, and written consent is obtained from the patient. [Cases of benign pancreatic disease(chornic pancreatitis) or common bile duct stones(normal pancreas)] -Cases of chronic pancreatitis- 1: The age at the time of consent is 18 years or older. 2: Prior imaging tests have confirmed that there are no findings suggestive of malignant pancreatic disease. 3: ERCP is scheduled for investigation of chronic pancreatitis 4: The patient is given an explanation using an explanatory document, and written consent is obtained from the patient. *However, if a patient is diagnosed with a malignant disease through cytology, the patient will not be included in this study. -Cases of common bile duct stones- 1: The age at the time of consent is 18 years or older. 2: Prior imaging tests have confirmed that there are no findings suggestive of pancreatic tumors or pancreatic diseases. 3: ERCP is scheduled for common bile duct stones. 4: The patient is given an explanation using an explanatory document, and written consent is obtained from the patient.
Exclusion criteria
Exclusion criteria: If any of the following applies to the patient, this patient will be excluded. 1: Those who have a history of malignant disease in the upper gastrointestinal tract (esophageal cancer, gastric cancer, duodenal papilla tumor, etc.) 2: Those who have a history of upper gastrointestinal surgery (gastrectomy, pancreaticoduodenectomy, upper gastrointestinal reconstruction, etc.) 3: There is obvious bile duct malignancy. 4: Those who have received preoperative chemotherapy for pancreatic ductal carcinoma at the time of registration or in the past. 5: Those who have a history of allergies to drugs used during endoscopic examinations. 6: Those who are judged by the attending physician to be ineligible for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We aim to develop a new method for early diagnosis of pancreatic cancer by analyzing the expression of S100P protein and miRNA in extracellular vesicles derived from blood, pancreatic juice, and duodenal fluid collected from patients with pancreatic cancer and benign disease. We will create ROC curves and calculate AUC for S100P protein concentration and expression of miRNA to evaluate diagnostic ability. Cut-off values will be calculated using the Youden index. Sensitivity and specificity will be calculated based on the obtained cut-off values, and compared with the diagnostic ability of pancreatic juice cytology. | — |
Countries
Japan
Contacts
Public ContactTomoyuki Araki
Kyushu university faculty of medical sciences Department of surgery and oncology
Outcome results
None listed